The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, one of which is Cenrifki (tolebrutinib), Sanofi's treatment for multiple sclerosis.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, one of which is Cenrifki (tolebrutinib), Sanofi's treatment for multiple sclerosis.